Celltrion has unveiled Phase III results for its biosimilar Truxima at the annual meeting of the American Society of Hematology (ASH), reported The Investor.
According to the company, Truxima was not inferior in terms of efficacy and safety for patients suffering advanced follicular lymphoma, compared to its reference drug, Roche's Rituxan.
The overall survival rate four years after receiving Truxima and Rituxan treatment was estimated to be around 88% and 93.3% respectively.
The biosimilar's progression-free survival rate was 60.9% and Rituxan's rate was 54.7%, while Truxima's time to progression was also similar to the original drug.
"The clinical trials were conducted among patients in European countries including Germany, Spain and Russia as well as Asian countries like Japan for 40 months," a Celltrion official said.
To read more NewsPoints articles, click here.